{"hands_on_practices": [{"introduction": "A cornerstone of expert clinical practice is the ability to synthesize a complex presentation into a coherent diagnostic and management plan. This first practice challenges you to act as the primary clinician for a patient with multiple cutaneous findings suggestive of a systemic disorder. Your task is to prioritize differential diagnoses and formulate a risk-aware, efficient investigative strategy, mirroring the high-level decision-making required in dermatology [@problem_id:4426844].", "problem": "A 42-year-old patient presents with hyperpigmented, velvety plaques over the posterior neck and axillae consistent with acanthosis nigricans, multiple sudden-onset pruritic yellow papules clustered over the extensor surfaces consistent with eruptive xanthomas, and thickened, discolored toenails with subungual debris suggestive of onychomycosis. There is no fever, no abdominal pain, and no history of pancreatitis. Body mass index (`BMI`) appears elevated on inspection. The clinician must prioritize a differential diagnosis and a first-line investigative strategy that is both efficient and risk-aware.\n\nUsing well-established definitions and clinical-pathophysiological principles, select the single best structured approach that most appropriately orders the differential and investigations, given the concurrent presence of acanthosis nigricans, eruptive xanthomas, and onychomycosis:\n\nFundamental base for reasoning:\n- Insulin resistance is a state in which target tissues have a reduced biological response to insulin, classically associated with acanthosis nigricans due to keratinocyte and dermal fibroblast growth factor signaling driven by hyperinsulinemia.\n- Eruptive xanthomas reflect deposition of triglyceride-rich lipoproteins in the dermis, classically seen when serum triglycerides are markedly elevated (often $>1000$ mg/dL), and signal risk for acute pancreatitis.\n- Diabetes mellitus increases susceptibility to dermatophyte infections, including onychomycosis, through hyperglycemia-related immune dysfunction and microangiopathy.\n- Primary and secondary dyslipidemias can be driven by endocrine disease; hypothyroidism elevates low-density lipoprotein (LDL) and triglycerides via reduced hepatic LDL receptor expression and altered lipoprotein metabolism.\n- Widely accepted diagnostic thresholds for diabetes mellitus include fasting plasma glucose $\\geq 126$ mg/dL, $2$-hour oral glucose tolerance test (OGTT) value $\\geq 200$ mg/dL, or Hemoglobin A1c (HbA1c) $\\geq 6.5\\%$.\n- The calculated LDL cholesterol using the Friedewald method is invalid when triglycerides are high (commonly cited at $\\geq 400$ mg/dL).\n\nWhich option best reflects a correct, prioritized, and comprehensive approach?\n\nA. Immediately prioritize the metabolic differential anchored in insulin resistance and secondary causes of severe hypertriglyceridemia: obtain fasting plasma glucose, Hemoglobin A1c (HbA1c), and, if indeterminate, an oral glucose tolerance test (OGTT); order a fasting lipid profile with triglycerides, total cholesterol, high-density lipoprotein (HDL), and low-density lipoprotein (LDL), recognizing that calculated LDL is invalid if triglycerides are markedly elevated; screen for hypothyroidism with thyroid-stimulating hormone (TSH) and free thyroxine (free $T4$); assess pancreatitis risk if triglycerides are very high (amylase/lipase if symptomatic), and evaluate secondary causes (alcohol intake, medications, nephrotic syndrome, renal and hepatic function tests); perform potassium hydroxide (KOH) preparation and fungal culture from the nail unit to confirm onychomycosis; reserve skin biopsy of xanthomas or acanthosis nigricans for atypical presentations (e.g., mucosal involvement, rapid progression, systemic symptoms) suggestive of paraneoplastic disease.\n\nB. Given acanthosis nigricans, first exclude occult gastrointestinal malignancy: proceed to upper endoscopy and computed tomography (CT) of chest/abdomen/pelvis; delay lipid testing and glycemic assessment until imaging is complete; begin empiric oral antifungal therapy for onychomycosis without mycological confirmation; consider biopsy of acanthosis nigricans before any metabolic work-up.\n\nC. Prioritize thyroid disease as the central etiology: begin levothyroxine empirically and order only TSH and free $T4$; biopsy any yellow papules to confirm xanthomas histologically; defer glycemic testing until after $6$ weeks of thyroid replacement; check a non-fasting lipid profile and calculate LDL regardless of triglyceride level.\n\nD. Focus on infection control first: obtain nail clippings for microscopy/culture and start systemic antibiotics for possible bacterial superinfection; assume the yellow papules arise from elevated LDL and start statin monotherapy without measuring triglycerides; do not order TSH or HbA1c until dermatologic lesions resolve.\n\nE. Obtain a non-fasting lipid panel and calculate LDL using the Friedewald equation even if triglycerides are high; treat presumed dyslipidemia before any glycemic evaluation; avoid pancreatitis screening unless abdominal pain develops; perform OGTT only after lipid-lowering therapy is completed; do not test for hypothyroidism unless the patient reports cold intolerance or weight gain.\n\nSelect the single best option.", "solution": "### Step 1: Extract Givens\n\nThe problem provides the following information about a patient and established medical principles:\n\n**Patient Presentation:**\n- Age: `$42$` years old.\n- Dermatological findings:\n    - Hyperpigmented, velvety plaques over the posterior neck and axillae, consistent with acanthosis nigricans.\n    - Multiple sudden-onset pruritic yellow papules clustered over the extensor surfaces, consistent with eruptive xanthomas.\n    - Thickened, discolored toenails with subungual debris, suggestive of onychomycosis.\n- Systemic status:\n    - No fever, no abdominal pain, no history of pancreatitis.\n    - Body mass index (`BMI`) appears elevated.\n\n**Task:**\n- Select the single best structured approach that most appropriately orders the differential diagnosis and investigations.\n\n**Fundamental Base for Reasoning:**\n1.  **Acanthosis Nigricans:** Associated with insulin resistance due to hyperinsulinemia-driven growth factor signaling.\n2.  **Eruptive Xanthomas:** Reflect deposition of triglyceride-rich lipoproteins in the dermis, seen with markedly elevated serum triglycerides (often $> 1000 \\text{ mg/dL}$), and signal risk for acute pancreatitis.\n3.  **Onychomycosis:** Susceptibility is increased by diabetes mellitus due to hyperglycemia-related immune dysfunction and microangiopathy.\n4.  **Secondary Dyslipidemia:** Hypothyroidism elevates low-density lipoprotein (`LDL`) and triglycerides.\n5.  **Diabetes Mellitus Diagnostic Criteria:** Fasting plasma glucose `\\geq 126 \\text{ mg/dL}`, `$2$-hour oral glucose tolerance test (`OGTT`) value `\\geq 200 \\text{ mg/dL}`, or Hemoglobin A1c (`HbA1c`) `\\geq 6.5\\%`.\n6.  **Friedewald Equation Limitation:** Calculated `LDL` cholesterol is invalid when triglycerides are high (commonly `\\geq 400 \\text{ mg/dL}`).\n\n### Step 2: Validate Using Extracted Givens\n\nThe problem statement is evaluated against the validation criteria:\n\n-   **Scientifically Grounded:** The problem describes a classic clinical triad of acanthosis nigricans, eruptive xanthomas, and onychomycosis. The association of these findings with an underlying metabolic disorder, specifically insulin resistance, uncontrolled diabetes mellitus, and severe hypertriglyceridemia, is a cornerstone of internal medicine and endocrinology. The provided \"Fundamental base for reasoning\" contains standard, factually correct pathophysiological principles and diagnostic criteria. The problem is firmly grounded in established medical science.\n-   **Well-Posed:** The task is to select the \"single best structured approach\" from a set of options. This requires prioritizing diagnoses and investigations based on clinical urgency and likelihood, which is a standard and well-posed problem in clinical reasoning. A unique best answer is derivable from established principles of medical practice.\n-   **Objective:** The presentation is described using standard clinical terminology. The provided principles are objective and quantitative where appropriate. The question is free of subjective or biased language.\n-   **Completeness and Consistency:** The problem provides sufficient information to formulate a robust differential diagnosis and a logical investigative plan. The patient's lack of abdominal pain is a crucial detail for risk stratification. There are no internal contradictions.\n-   **Realism:** The clinical scenario is highly realistic and represents a type of case commonly encountered in primary care, endocrinology, and dermatology clinics.\n\nThe problem statement does not violate any of the invalidity criteria. It is a valid, well-posed, and scientifically sound clinical reasoning problem.\n\n### Step 3: Action\n\nThe problem is valid. Proceed to the solution and option-by-option analysis.\n\n### Solution Derivation\n\nThe patient presents a constellation of signs that strongly point to a central, unifying process: a severe, uncontrolled metabolic disorder. The logical approach is to break down the presentation into its constituent parts and identify the common underlying pathophysiology.\n\n1.  **Acanthosis Nigricans:** A reliable cutaneous marker of insulin resistance and the associated hyperinsulinemia.\n2.  **Eruptive Xanthomas:** Pathognomonic for severe hypertriglyceridemia. Based on the provided principles, this implies serum triglycerides are likely well over `$400 \\text{ mg/dL}` and possibly $ > 1000 \\text{ mg/dL}$. This constitutes a medical urgency due to the high risk of acute pancreatitis, even in an currently asymptomatic patient.\n3.  **Onychomycosis:** While common in the general population, its presence in this context reinforces the suspicion of an immunocompromised state, with uncontrolled diabetes mellitus being the most likely cause.\n4.  **Elevated `BMI`:** Consistent with the metabolic syndrome, insulin resistance, and type 2 diabetes.\n\n**Synthesis and Prioritization:**\nThe unifying diagnosis is most likely severe, uncontrolled type 2 diabetes mellitus with secondary severe hypertriglyceridemia, manifesting as the metabolic syndrome. The immediate priorities are:\na.  **Assess and quantify the metabolic derangements:** This means urgently measuring fasting glucose, `HbA1c`, and a fasting lipid panel. The triglyceride level is critical for assessing pancreatitis risk.\nb.  **Investigate secondary causes:** While uncontrolled diabetes is a potent cause of hypertriglyceridemia, other common secondary causes must be ruled out. Hypothyroidism is a classic and easily testable example. Basic metabolic and hepatic function panels are also necessary to rule out renal or liver disease and to establish a baseline for potential pharmacotherapy.\nc.  **Confirm peripheral diagnoses as needed:** The diagnosis of onychomycosis should be confirmed by microscopy (`KOH` preparation) and/or culture before initiating systemic antifungal agents, which carry risks of toxicity and drug interactions. The diagnoses of acanthosis nigricans and eruptive xanthomas are typically clinical, and biopsy is reserved for atypical cases. Malignancy-associated acanthosis nigricans is rare and a much less likely diagnosis than the metabolic form in this classic setting.\n\nA correct approach must therefore prioritize the assessment of glycemic control and hypertriglyceridemia, screen for key secondary causes like hypothyroidism, and manage diagnostic confirmation of the dermatologic findings appropriately without delaying the central metabolic workup.\n\n### Option-by-Option Analysis\n\n**A. Immediately prioritize the metabolic differential anchored in insulin resistance and secondary causes of severe hypertriglyceridemia: obtain fasting plasma glucose, Hemoglobin A1c (HbA1c), and, if indeterminate, an oral glucose tolerance test (OGTT); order a fasting lipid profile with triglycerides, total cholesterol, high-density lipoprotein (HDL), and low-density lipoprotein (LDL), recognizing that calculated LDL is invalid if triglycerides are markedly elevated; screen for hypothyroidism with thyroid-stimulating hormone (TSH) and free thyroxine (free T4); assess pancreatitis risk if triglycerides are very high (amylase/lipase if symptomatic), and evaluate secondary causes (alcohol intake, medications, nephrotic syndrome, renal and hepatic function tests); perform potassium hydroxide (KOH) preparation and fungal culture from the nail unit to confirm onychomycosis; reserve skin biopsy of xanthomas or acanthosis nigricans for atypical presentations (e.g., mucosal involvement, rapid progression, systemic symptoms) suggestive of paraneoplastic disease.**\n\nThis option correctly identifies the central issue as a metabolic disorder driven by insulin resistance. It proposes the correct first-line tests for diabetes (`fasting plasma glucose`, `HbA1c`) and dyslipidemia (fasting lipid profile). It correctly notes the limitation of the Friedewald calculation for `LDL`. It includes a crucial screen for hypothyroidism (`TSH`, `free T4`). It outlines a rational approach to pancreatitis risk and other secondary causes. It correctly advocates for mycological confirmation of onychomycosis before treatment and appropriately reserves skin biopsy for atypical cases. This approach is logical, comprehensive, correctly prioritized, and aligns with established clinical principles.\n\n**Verdict: Correct**\n\n**B. Given acanthosis nigricans, first exclude occult gastrointestinal malignancy: proceed to upper endoscopy and computed tomography (CT) of chest/abdomen/pelvis; delay lipid testing and glycemic assessment until imaging is complete; begin empiric oral antifungal therapy for onychomycosis without mycological confirmation; consider biopsy of acanthosis nigricans before any metabolic work-up.**\n\nThis option demonstrates fatally flawed prioritization. While malignant acanthosis nigricans exists, it is far less common than the metabolic form. In a patient with a classic metabolic syndrome phenotype (elevated `BMI`, eruptive xanthomas), prioritizing a massive malignancy workup is incorrect. Delaying the assessment of glucose and lipids is dangerous, as it leaves the patient at unmitigated risk for diabetic ketoacidosis/hyperosmolar hyperglycemic state and acute pancreatitis. Empiric antifungal therapy without confirmation is poor practice.\n\n**Verdict: Incorrect**\n\n**C. Prioritize thyroid disease as the central etiology: begin levothyroxine empirically and order only TSH and free T4; biopsy any yellow papules to confirm xanthomas histologically; defer glycemic testing until after 6 weeks of thyroid replacement; check a non-fasting lipid profile and calculate LDL regardless of triglyceride level.**\n\nThis option incorrectly prioritizes hypothyroidism as the central etiology over the much more evident signs of severe insulin resistance and likely diabetes. Starting levothyroxine empirically without a biochemical diagnosis is inappropriate. Biopsy of classic eruptive xanthomas is unnecessary. Deferring glycemic testing is dangerous. Ordering a non-fasting lipid profile is incorrect for assessing triglycerides, and calculating `LDL` when triglycerides are high is explicitly wrong, as stated in the problem's own premises.\n\n**Verdict: Incorrect**\n\n**D. Focus on infection control first: obtain nail clippings for microscopy/culture and start systemic antibiotics for possible bacterial superinfection; assume the yellow papules arise from elevated LDL and start statin monotherapy without measuring triglycerides; do not order TSH or HbA1c until dermatologic lesions resolve.**\n\nThis option incorrectly prioritizes the onychomycosis, which is the least acute problem. It incorrectly suggests antibiotics for a fungal infection with no signs of superinfection. It makes a grave pathophysiological error by attributing eruptive xanthomas to `LDL` instead of triglycerides and consequently proposes incorrect therapy (statin monotherapy) while dangerously ignoring the need to measure triglycerides. Delaying the core metabolic workup is negligent.\n\n**Verdict: Incorrect**\n\n**E. Obtain a non-fasting lipid panel and calculate LDL using the Friedewald equation even if triglycerides are high; treat presumed dyslipidemia before any glycemic evaluation; avoid pancreatitis screening unless abdominal pain develops; perform OGTT only after lipid-lowering therapy is completed; do not test for hypothyroidism unless the patient reports cold intolerance or weight gain.**\n\nThis option contains multiple errors. A non-fasting lipid panel is inadequate. Using the Friedewald equation with high triglycerides is invalid. Separating lipid and glycemic evaluation is illogical since they are intertwined; uncontrolled glucose is a major driver of high triglycerides. Performing an `OGTT` *after* lipid therapy is nonsensical. Failing to screen for hypothyroidism based on the presence of severe dyslipidemia (a classic indication for screening) is a clinical oversight.\n\n**Verdict: Incorrect**", "answer": "$$\\boxed{A}$$", "id": "4426844"}, {"introduction": "Following an initial assessment, clinical reasoning often shifts from broad differential diagnoses to quantifying the likelihood of a specific condition. This exercise demonstrates the power of Bayesian updating in clinical practice, showing how to systematically combine the evidence from multiple cutaneous signs. By using likelihood ratios for independent findings, you can refine a general suspicion into a precise post-test probability of disease [@problem_id:4426859].", "problem": "A clinician in dermatology evaluates a patient with hyperpigmented, velvety plaques on the posterior neck and axillae consistent with acanthosis nigricans, along with multiple acrochordons (skin tags) on the trunk. In the context of suspected insulin resistance, the clinician wishes to update the probability of insulin resistance based on the presence of these two cutaneous findings. The initial (pre-test) probability of insulin resistance is $0.4$. The positive likelihood ratio (LR+) for acanthosis nigricans is $LR_+ = 3$, and the positive likelihood ratio (LR+) for multiple skin tags is $LR_+ = 2$. Assume that, conditional on the presence or absence of insulin resistance, these two findings contribute independent evidence.\n\nUsing a Bayesian update grounded in the definitions of probability, odds, and positive likelihood ratio, determine the posterior probability of insulin resistance after observing both findings. Choose the single best answer.\n\nA. $0.80$\nB. $0.85$\nC. $0.67$\nD. $0.57$", "solution": "The problem statement will first be validated for scientific and logical soundness.\n\n**Step 1: Extract Givens**\n- Initial (pre-test) probability of insulin resistance, $P(IR) = 0.4$.\n- The patient presents with acanthosis nigricans (AN) and multiple skin tags (ST).\n- The positive likelihood ratio for acanthosis nigricans is $LR_{+,AN} = 3.0$.\n- The positive likelihood ratio for multiple skin tags is $LR_{+,ST} = 2.0$.\n- The two findings, AN and ST, are assumed to contribute independent evidence conditional on the presence or absence of insulin resistance.\n\n**Step 2: Validate Using Extracted Givens**\n- **Scientifically Grounded:** The problem is scientifically sound. The association between cutaneous findings like acanthosis nigricans and acrochordons (skin tags) with insulin resistance is a well-established concept in dermatology and endocrinology. The use of likelihood ratios and Bayesian updating is a standard and rigorous method in evidence-based medicine for revising probabilities based on new clinical evidence. The given numerical values for probability and likelihood ratios are plausible in a clinical context.\n- **Well-Posed:** The problem is well-posed. It provides all necessary information: a pre-test probability, likelihood ratios for two separate findings, and a crucial assumption of conditional independence that allows for the combination of evidence. The question asks for a specific, calculable quantity (posterior probability).\n- **Objective:** The problem is stated in objective, quantitative terms, free from ambiguity or subjective language.\n\n**Step 3: Verdict and Action**\nThe problem is valid. A solution will be derived.\n\n**Derivation of the Solution**\nThe problem requires updating a pre-test probability of a condition (insulin resistance, $IR$) given two positive findings (acanthosis nigricans, $AN$, and skin tags, $ST$). The most direct method is to use the odds-likelihood ratio formulation of Bayes' theorem.\n\nFirst, we define the relevant quantities:\n- $P(IR)$: The prior probability of insulin resistance.\n- $P(IR | AN \\cap ST)$: The posterior probability of insulin resistance given that both findings are present.\n- $Odds(IR) = \\frac{P(IR)}{1-P(IR)}$: The prior odds of insulin resistance.\n- $Odds(IR | AN \\cap ST) = \\frac{P(IR | AN \\cap ST)}{1-P(IR | AN \\cap ST)}$: The posterior odds of insulin resistance.\n- $LR_{+,AN} = \\frac{P(AN|IR)}{P(AN|\\neg IR)}$: The positive likelihood ratio for acanthosis nigricans.\n- $LR_{+,ST} = \\frac{P(ST|IR)}{P(ST|\\neg IR)}$: The positive likelihood ratio for skin tags.\n\nThe update rule in odds form is:\n$$ \\text{Posterior Odds} = \\text{Prior Odds} \\times \\text{Likelihood Ratio} $$\n\n**Step 1: Calculate the Prior Odds**\nThe given prior probability is $P(IR) = 0.4$.\nThe prior odds are:\n$$ Odds(IR) = \\frac{0.4}{1 - 0.4} = \\frac{0.4}{0.6} = \\frac{2}{3} $$\n\n**Step 2: Combine the Likelihood Ratios**\nThe problem states that the two findings are conditionally independent. This means the probability of observing both findings given the presence of the disease is the product of the individual probabilities, and similarly for the absence of the disease.\n$$ P(AN \\cap ST | IR) = P(AN | IR) \\times P(ST | IR) $$\n$$ P(AN \\cap ST | \\neg IR) = P(AN | \\neg IR) \\times P(ST | \\neg IR) $$\nTherefore, the combined likelihood ratio for observing both findings, $LR_{+,combined}$, is the product of the individual likelihood ratios:\n$$ LR_{+,combined} = \\frac{P(AN \\cap ST | IR)}{P(AN \\cap ST | \\neg IR)} = \\frac{P(AN | IR) \\times P(ST | IR)}{P(AN | \\neg IR) \\times P(ST | \\neg IR)} = \\left(\\frac{P(AN|IR)}{P(AN|\\neg IR)}\\right) \\times \\left(\\frac{P(ST|IR)}{P(ST|\\neg IR)}\\right) $$\n$$ LR_{+,combined} = LR_{+,AN} \\times LR_{+,ST} = 3 \\times 2 = 6 $$\n\n**Step 3: Calculate the Posterior Odds**\nUsing the update rule, we multiply the prior odds by the combined likelihood ratio to get the posterior odds.\n$$ Odds(IR | AN \\cap ST) = Odds(IR) \\times LR_{+,combined} $$\n$$ Odds(IR | AN \\cap ST) = \\frac{2}{3} \\times 6 = 4 $$\n\n**Step 4: Convert Posterior Odds to Posterior Probability**\nFinally, we convert the posterior odds back to a probability using the formula $P = \\frac{Odds}{1 + Odds}$.\n$$ P(IR | AN \\cap ST) = \\frac{Odds(IR | AN \\cap ST)}{1 + Odds(IR | AN \\cap ST)} = \\frac{4}{1 + 4} = \\frac{4}{5} $$\n$$ P(IR | AN \\cap ST) = 0.8 $$\nThe posterior probability of insulin resistance after observing both acanthosis nigricans and multiple skin tags is $0.80$.\n\n**Evaluation of Options**\n\n**A. $0.80$**\nThis value matches the derived posterior probability of $0.8$.\n**Verdict: Correct**\n\n**B. $0.85$**\nThis value is incorrect. It may arise from an arithmetic error or a conceptual misunderstanding. For instance, if one incorrectly started with a prior probability of $0.5$ (prior odds of $1$), the posterior odds would be $1 \\times 6 = 6$, leading to a posterior probability of $6 / (1+6) = 6/7 \\approx 0.857$. This is not the correct calculation based on the provided data.\n**Verdict: Incorrect**\n\n**C. $0.67$**\nThis value is incorrect. A value of $0.67$ is approximately $2/3$. This error likely stems from updating the probability with only one of the findings. If we only use the $LR_{+,AN} = 3$:\nPosterior Odds = Prior Odds $\\times LR_{+,AN} = \\frac{2}{3} \\times 3 = 2$.\nPosterior Probability = $\\frac{2}{1+2} = \\frac{2}{3} \\approx 0.67$.\nThis calculation erroneously ignores the evidence from the second finding (skin tags).\n**Verdict: Incorrect**\n\n**D. $0.57$**\nThis value is incorrect. A value of $0.57$ is approximately $4/7$. This error is analogous to option C, but uses the other likelihood ratio. If we only use the $LR_{+,ST} = 2$:\nPosterior Odds = Prior Odds $\\times LR_{+,ST} = \\frac{2}{3} \\times 2 = \\frac{4}{3}$.\nPosterior Probability = $\\frac{4/3}{1+4/3} = \\frac{4/3}{7/3} = \\frac{4}{7} \\approx 0.571$.\nThis calculation erroneously ignores the evidence from the first finding (acanthosis nigricans).\n**Verdict: Incorrect**", "answer": "$$\\boxed{A}$$", "id": "4426859"}, {"introduction": "Effective patient management extends beyond accurate diagnosis to the critical evaluation of therapeutic options. This final practice moves into the realm of evidence-based therapy, requiring you to translate research findings into clinically meaningful metrics. You will calculate the Absolute Risk Reduction ($ARR$) and Number Needed to Treat ($NNT$), essential skills for interpreting clinical trial data and making informed treatment recommendations [@problem_id:4426797].", "problem": "A dermatology service runs a pragmatic, randomized study in adults with long-standing Type 2 diabetes mellitus and autoimmune thyroiditis with subclinical hypothyroidism, both conditions known to contribute to xerosis and plantar heel fissuring as cutaneous manifestations. Participants have symmetric dry, scaly heels without active ulceration at baseline. The intervention group applies $10\\%$ urea cream nightly; the control group uses a plain emollient. Over a $1$-year horizon, the control arm has a baseline fissure incidence of $15\\%$ per year. The intervention is observed to produce a relative risk reduction of $40\\%$ for new heel fissures compared to control.\n\nUsing only foundational epidemiologic definitions appropriate for clinical outcomes in dermatology and venereology, derive the absolute risk reduction over one year and then compute the Number Needed to Treat (NNT) over one year to prevent one fissure event. Express the absolute risk reduction as a decimal risk (for example, $0.06$), not with a percentage sign. Round the NNT to two significant figures. Provide your final answer as a two-entry row in the form $\\left(\\text{absolute risk reduction}, \\text{NNT}\\right)$.", "solution": "The problem is first validated against the established criteria.\n\n### Step 1: Extract Givens\n-   Population: Adults with long-standing Type 2 diabetes mellitus and autoimmune thyroiditis with subclinical hypothyroidism.\n-   Intervention: $10\\%$ urea cream nightly.\n-   Control: Plain emollient.\n-   Study Horizon: $1$ year.\n-   Control Event Rate ($CER$): Baseline fissure incidence in the control arm is $15\\%$ per year.\n-   Relative Risk Reduction ($RRR$): The intervention produces a relative risk reduction of $40\\%$ for new heel fissures compared to control.\n-   Required Outputs:\n    1.  Absolute risk reduction ($ARR$) over one year, as a decimal risk.\n    2.  Number Needed to Treat ($NNT$) over one year, rounded to two significant figures.\n\n### Step 2: Validate Using Extracted Givens\nThe problem is scientifically grounded, describing a plausible clinical scenario in dermatology. The underlying conditions (diabetes, hypothyroidism) are known risk factors for xerosis and fissuring, and urea cream is a standard treatment. The epidemiological concepts—$CER$, $RRR$, $ARR$, and $NNT$—are standard and well-defined. The data provided ($CER = 15\\%$, $RRR = 40\\%$) are sufficient and consistent for the calculation of the required quantities. The problem is well-posed, objective, and does not violate any of the specified invalidity criteria.\n\n### Step 3: Verdict and Action\nThe problem is valid. A solution will be derived.\n\nThe problem requires the calculation of the Absolute Risk Reduction ($ARR$) and the Number Needed to Treat ($NNT$) based on the provided Control Event Rate ($CER$) and Relative Risk Reduction ($RRR$).\n\nThe given values are:\n-   The Control Event Rate, $CER$, which is the incidence of new fissures in the control group:\n    $$ CER = 15\\% = 0.15 $$\n-   The Relative Risk Reduction, $RRR$:\n    $$ RRR = 40\\% = 0.40 $$\n\nLet $IER$ represent the Intervention Event Rate, which is the incidence of new fissures in the group receiving the $10\\%$ urea cream.\n\nThe Relative Risk Reduction ($RRR$) is defined as the proportional reduction in the event rate in the intervention group compared to the control group. The formula is:\n$$ RRR = \\frac{CER - IER}{CER} $$\nWe can use this relationship to find the $IER$. Rearranging the formula:\n$$ IER = CER \\times (1 - RRR) $$\nSubstituting the given values:\n$$ IER = 0.15 \\times (1 - 0.40) $$\n$$ IER = 0.15 \\times 0.60 $$\n$$ IER = 0.09 $$\nSo, the event rate in the intervention group is $9\\%$.\n\nNext, we calculate the Absolute Risk Reduction ($ARR$). The $ARR$ is the absolute difference in the event rates between the control and intervention groups. The formula is:\n$$ ARR = CER - IER $$\nSubstituting the values for $CER$ and the calculated $IER$:\n$$ ARR = 0.15 - 0.09 $$\n$$ ARR = 0.06 $$\nThis is the first required value, expressed as a decimal risk.\n\nFinally, we compute the Number Needed to Treat ($NNT$). The $NNT$ is the reciprocal of the $ARR$. It represents the average number of patients who need to be treated with the intervention for the specified time period (here, $1$ year) to prevent one additional adverse outcome (a new heel fissure).\nThe formula is:\n$$ NNT = \\frac{1}{ARR} $$\nSubstituting the calculated value for $ARR$:\n$$ NNT = \\frac{1}{0.06} $$\n$$ NNT = \\frac{1}{\\frac{6}{100}} = \\frac{100}{6} = \\frac{50}{3} $$\n$$ NNT \\approx 16.666... $$\nThe problem requires rounding the $NNT$ to two significant figures. The first two significant figures are $1$ and $6$. The third digit is $6$, which is greater than or equal to $5$, so we round up the second significant figure.\n$$ NNT \\approx 17 $$\n\nThe two required values are the absolute risk reduction, $0.06$, and the Number Needed to Treat, $17$. The final answer is presented as a two-entry row matrix as requested.", "answer": "$$\n\\boxed{\\begin{pmatrix} 0.06 & 17 \\end{pmatrix}}\n$$", "id": "4426797"}]}